-0,84 %
+0,43 %
+17,27 %
-21,33 %
-7,45 %
+35,83 %
+7,89 %
-29,10 %
-81,25 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Læs mereMarkedsværdi
50,04 mio. EUR
Aktieomsætning
14,69 t EUR
P/E (adj.) (26e)
-15,33
EV/EBIT (adj.) (26e)
-13,64
P/B (26e)
6,44
EV/S (26e)
5.580,3
Udbytteafkast, % (26e)
-
